NCT04893096 - MOR202 for Refractory MN | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

February 21, 2025

Study Completion Date

February 21, 2025

Conditions

Membranous Nephropathy

Interventions

DRUG

MOR202

Each patient will be treated for 24 weeks and received a total of 9 doses. During the first treatment cycle, MOR202 will be administered weekly. For the following 5 months, patients will receive one dose every 4 weeks.

Trial Locations (2)

24020

"Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò", Ranica

24100

ASST HPG23 - Unità di Nefrologia, Bergamo